Echo Therapeutics Net Income

The latest net income for ECTE is $-6M as of September 2016. That compares with $-24M in the prior-year period — up 74.7% year over year. That is below the sector sector average of $100M. Investors often review this figure alongside Echo Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, ECTE's net income moved from $-24M to $-6M — a 74.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Echo Therapeutics's operating scale or balance-sheet position.

Against its sector companies, ECTE currently prints $-6M for net income, while the sector average sits near $100M. That is roughly 105.8% below the sector mean. Large gaps often invite a closer look at Echo Therapeutics's growth, margins, and balance sheet.

A net income figure of $-6M for ECTE is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $100M. Explore the charts below for those layers of context.

After noting ECTE's net income ($-6M), review year-over-year change from $-24M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.